Clozapine re-exposure after dilated cardiomyopathy
| Authors | Mariëtte Nederlof, Theo WJ Benschop, Cornelia Adriana de Vries Feyens, Rob Heerdink |
|---|---|
| Published in | BMJ Case Reports: publishing, sharing and learning through experience |
| Publication date | 27 mei 2017 |
| Research groups | Duurzame Farmaceutische Zorg |
| Type | Article |
Summary
from the publishers' website: "A 63-year-old woman with diabetes type II and a history of breast cancer was treated with clozapine for her refractory schizophrenia. She developed a dilated cardiomyopathy with an ejection fraction of 25%, a life-threatening event. The cause of heart failure could be multifactorial, with clozapine, family history, chemotherapy, diabetes type II and/or lithium as possible contributing risk factors. Clozapine was discontinued and the patient was referred to a hospice. Two weeks later, her heart failure slowly improved. Subsequently, she became extremely psychotic with a severe decline in quality of life. Therefore, it was decided to restart clozapine under cardiac monitoring. The patient’s psychotic symptoms improved and her heart failure status remained stable for more than a year. Thereafter, a small deterioration was seen in cardiac function. In this case, re-exposure to clozapine was successful for at least 2 years."
On this publication contributed
| Language | Engels |
|---|---|
| Published in | BMJ Case Reports: publishing, sharing and learning through experience |
| Key words | Clozapine |
Neem contact met ons op
- Telephone 088 481 81 81
- Email info@hu.nl
-
Send us a message or add +97010241111 to the contact list on your mobile phone and send us your question via WhatsApp.
- Bereikbaar op ma t/m vrij 09.30 - 16.30 uur.